Cost-Effectiveness Analysis of the Hypertension Treatment; pursuing cost reduction of national health expenditure

2014 Fiscal Year Final Research Report

• Project/Area Number: 24530239
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Applied economics
• Research Institution: Tohoku University
• Principal Investigator: SATO MIHO 東北大学, 医学(系)研究科(研究院), 大学院非常勤講師 (70579622)
• Co-Investigator(Kenkyū-buntansha): KAKIHARA Hiroaki 京都大学, 大学院薬学研究科, 教授 (20351314)
• Co-Investigator(Renkei-kenkyūsha): TAKASE Kei 東北大学, 大学病院, 教授 (60361094) ; SEIJI Kazumasa 東北大学, 大学病院, 講師 (50400247) ; MORIMOTO Ryo 東北大学, 大学病院, 助教 (30547394)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 費用対効果 / 原発性アルドステロン症 / 副腎静脈サンプリング

Outline of Final Research Achievements

Approximately 10% of cases of hypertension in Japan are caused by primary aldosteronism (PA), amounting to about 4 million patients in total. Primary aldosteronism due to unilateral aldosterone hypersecretion is potentially curable by adrenalectomy. The clinical benefits of identifying and treating PA have been reported internationally, but its cost-effectiveness is unclear. We examined whether diagnosing and treating hidden PA in hypertensive population was cost-effective compared with suboptimal treatment. We established a Markov decision model based on plausible clinical pathways and prognoses of PA. The result was cost-effective, but our findings were sensitive to the outcomes of screening and treatment, and the costs of continuous or periodic medication for hypertension and the treatment of stroke and its complications.

Free Research Field

医療経済学